{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:32:15Z","timestamp":1786977135823,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The use of immune checkpoint inhibitors, particularly PD\u20101 inhibitors, has revolutionized the treatment of advanced tumors and shown significant improvements in patient survival rates. However, which PD\u20101 inhibitor is more effective and safer for a specific indication remains unclear. To address this problem, our study aimed to evaluate the effectiveness and safety of different PD\u20101 inhibitors in combination with chemotherapy as first\u2010line therapy for individuals with advanced non\u2010small\u2010cell lung cancer (NSCLC) without driver genes in the real world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of individuals diagnosed with aNSCLC who received immune checkpoint inhibitors (ICIs) with modified PD\u20101 inhibitors, including Sintilimab, Toripalimab, Tislelizumab, Camrelizumab, or Pembrolizumab as first\u2010line treatment between March 5th, 2016 and October 20th, 2022. We assessed demographic and clinical information and analyzed clinical response, survival outcomes, and safety profiles. The primary endpoint was overall survival (OS), and the secondary endpoints included progression\u2010free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of the date cut\u2010off on October 20th, 2022, the median follow\u2010up time was 20.62\u2009months. A total of 204 patients were enrolled in the study, including 56 (27.5%) patients receiving modified PD\u20101 inhibitors (Sintilimab, Toripalimab, Tislelizumab, or Camrelizumab) in combination with chemotherapy and 148 (72.5%) patients receiving Pembrolizumab in combination with chemotherapy. In the overall cohort, the median overall survival (OS) was 26.9\u2009months (95%CI, 22.3\u201331.6), the median progression\u2010free survival (PFS) was 8.4\u2009months (95%CI, 6.9\u20139.8), and the objective response rate (ORR) and disease control rate (DCR) were 47.6% (95%CI, 29.9\u201343.6) and 84.3% (95%CI, 78.4\u201388.9). The mOS of modified PD\u20101 inhibitors group and Pembrolizumab group were 30.7 (95%CI, 17.3\u201344.4) months and 26.8 (95%CI, 22.2\u201331.4) months. The mPFS of two groups were 8.3(95%CI, 6.9\u20139.6) months and 8.8 (95%CI, 6.9\u201310.7) months, respectively. There was no statistical difference between the two groups in terms of OS or PFS. The ORR for the two groups was 48.2% (95%CI, 34.8\u201361.8) and 47.3% (95%CI, 39.1\u20135.6), respectively. However, due to the limited sample size, the difference was not statistically significant. On the other hand, the DCR tended to be higher in the Pembrolizumab group (86.5%; 95%CI, 79.7\u201391.4) compared to the modified PD\u20101 inhibitors group (78.6%; 95%CI, 65.2\u201387.9), and this difference was statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). In terms of safety, both groups exhibited favorable clinical safety profiles. The only two types of potentially immune\u2010related adverse events reported were pneumonitis and reactive cutaneous capillary endothelial proliferation (RCCEP).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The modified PD\u20101 inhibitors showed comparable survival outcomes and manageable safety profiles in NSCLC compared to Pembrolizumab. Moreover, these inhibitors exhibited improved accessibility and economic outcomes compared to Pembrolizumab. While there were similarities in drug\u2010related and immunotherapy\u2010related adverse reactions between the modified PD\u20101 inhibitors and Pembrolizumab, there were some slight differences. Further prospective and retrospective studies would be necessary to validate these findings beyond the scope of the CTONG1901 study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.7024","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T03:49:46Z","timestamp":1708746586000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A multicenter, real\u2010world study on effectiveness and safety of first\u2010line modified\n                    <scp>PD<\/scp>\n                    \u20101 inhibitors with chemotherapy in advanced non\u2010small cell lung cancer (\n                    <scp>aNSCLC<\/scp>\n                    ) with drive gene\u2010negative"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-4794","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"first","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[{"name":"Internal Medicine Emergency Department The Second Hospital of Beijing  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Nutrition, The First Medical Center Chinese PLA General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapei","family":"Qin","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupeng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Dong","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-2422","authenticated-orcid":false,"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-5692","authenticated-orcid":false,"given":"Yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA  Beijing China"},{"name":"Department of Oncology, the First Medical Center Chinese PLA General Hospital; Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs Ministry of Education  China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002108"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00727"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9032"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.21037\/qims.2018.08.02"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00886-2"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100465"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107594"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5440"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.743558"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.935581"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmab020"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1654303"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221111296"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13102"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/celldisc.2017.4"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13817"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2125799"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.728440"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00030-4"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S372276"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.7024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T02:06:51Z","timestamp":1712628411000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.7024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/cam4.7024"],"URL":"https:\/\/doi.org\/10.1002\/cam4.7024","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e7024"}}